ArticleThe oncologist2026
Cost implications of early treatment discontinuation in cancer: a real-world data analysis.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHealth care costs are rising due to increasing cancer incidence and the expanding use of high-cost anticancer medicines. Early treatment discontinuation (ETD) may signal inefficiencies in medicine use or reflect appropriate or inevitable clinical decisions. Despite its clinical and economic relevance, national-level data on ETD remain limited. This study aims to quantify ETD rates and associated costs for the highest budget anticancer medicines in the Netherlands and assess trends from 2018 to 2022.
methodsWe performed a retrospective analysis using real-world data from the Dutch national claims database. ETD was defined as treatment discontinued within 90 days. The study focused on the 30 highest-budget impact anticancer medicines in 2022, assessing ETD rates, related medicine costs, and trends over 5 years (2018-2022).
resultsIn 2022, these medicines accounted for €783 million in expenditures, with ETD representing 9.9% (€77 million). Among 30 343 treatments, 29.7% (9025) were discontinued within 90 days. From 2018 to 2022, total medication costs increased by 27.1%, while ETD costs rose by 9.6%. ETDs increased from 7287 to 9025 (+23.9%), with substantial variation among medicines. For most medicines, survivors accounted for most ETD spending, while ETD followed by death remained 9%.
conclusionsApproximately 30% of anticancer treatments are discontinued early, accounting for nearly 10% of medicine costs. While ETD highlights opportunities to improve efficiency, it also includes clinically justified and unavoidable discontinuations. Efforts to reduce avoidable ETD through improved patient selection, toxicity prediction, and treatment optimization are essential for more rational and equitable use of high-cost anticancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.